ArticleBMC chemistry2026
Development and validation of stability indicating RP-HPLC method for the simultaneous estimation of dapagliflozin and eplerenone in bulk and synthetic mixture.
Article in BMC chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A stability-indicating analytical method utilizing reverse-phase high-performance liquid chromatography was developed and validated for the simultaneous quantification of dapagliflozin and eplerenone in bulk drug materials and a laboratory-prepared synthetic mixture. Chromatographic separation was achieved on a Shim-pack C18 column (250 × 4.6 mm, 5 μm) using an isocratic elution of methanol and water (80:20, v/v) at a constant flow rate of 1.0 mL/min. Detection was carried out with a photodiode array detector set at 265 nm. The method exhibited a linear response across concentration ranges of 1-5 µg/mL for dapagliflozin and 2.5-12.5 µg/mL for eplerenone, with correlation coefficients exceeding 0.999. Validation studies, conducted in accordance with the International Council for Harmonization (ICH-International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) Q2(R2) guidelines, confirmed that the method was precise, accurate, robust, specific, and sensitive. The stability-indicating capability was verified through forced degradation experiments under acidic, alkaline, oxidative, thermal, and photolytic stress conditions, where degradation products were adequately resolved from the parent compounds using the developed method. The validated method was successfully applied to the analysis of a synthetic mixture, yielding assay results of 99.56% for dapagliflozin and 99.48% for eplerenone. Therefore, the proposed method is suitable for routine quality control analysis and stability studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.